Swiss Dental Startup vVARDIS Begins Trading on NYSE
vVARDIS debuted on the New York Stock Exchange under ticker VVVV, offering a drill-free cavity treatment targeting the world's most common non-communicable disease.
Swiss dental health company vVARDIS began trading on the New York Stock Exchange on Nov. 13, 2026, under the ticker symbol VVVV, marking a significant milestone for a startup that has built its business around treating tooth decay without traditional drilling.
The company was co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, who have positioned vVARDIS around a core clinical argument: cavities represent the world's most prevalent non-communicable disease, yet existing treatment options have changed little in decades. The founders say their technology offers a drill-free alternative designed to address that gap at scale.
Read more Windward Bio Debuts on Nasdaq, Shares Jump 68% at Close →
The NYSE listing elevates vVARDIS from a privately held dental innovator to a publicly accountable company with access to capital markets, a transition that will subject its growth strategy and financial performance to quarterly scrutiny from institutional and retail investors alike. The public debut also signals growing investor appetite for consumer health companies that challenge conventional clinical procedures.
Tooth decay affects a substantial share of the global population across all age groups, and the dental care market has historically been dominated by established device and pharmaceutical manufacturers. By targeting cavity treatment specifically with a non-invasive approach, vVARDIS is entering a competitive but underserved segment where patient comfort and accessibility are increasingly influential purchasing factors.
Continue reading at All Financial Services & Investing.
